Companies addressing diabetic retinopathy are involved in the development, manufacturing, and distribution of products and technologies aimed at diagnosing, treating, and managing this diabetic complication affecting the eyes. Diabetic retinopathy is a condition where high blood sugar levels damage blood vessels in the retina, leading to vision problems and potential blindness.
Regenerxbio Announced positive interim data from the ongoing Phase II ALTITUDE trial for RGX-314, a potential treatment for diabetic retinopathy without center-involved diabetic macular edema (CI-DME).
Eyenuk Received FDA clearance for its EyeArt® AI system with enhanced features, expanding capabilities for autonomous AI detection of various stages of diabetic retinopathy in primary care settings.
Exonate Successfully completed a Phase Ib/IIa trial for EXN407, a topical candidate with the potential to be the first topical treatment for diabetic retinopathy and diabetic macular edema.
Roche Diagnostics Introduced the Elecsys BRAF V600E Mutation Test, aiding in targeted treatment decisions for melanoma patients, who are also at risk for diabetic retinopathy.Medtronic: Continues to develop its portfolio of minimally invasive surgical instruments and energy devices for diabetic retinopathy treatment.
List of Diabetic Retinopathy Key Companies in the Market
Diabetic Retinopathy Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)